Early Long-Acting Injectables in Schizophrenia: A Manufacturer-Funded Narrative Case

This narrative review argues for repositioning long-acting injectable antipsychotics as first-line therapy within the first 5 years of schizophrenia, a stance relevant to ambulatory adherence and relapse-prevention workflows.

long-acting injectable antipsychoticspaliperidone palmitaterisperidone LAIaripiprazoleschizophreniaearly phase psychosismedication adherencerelapse preventionnarrative reviewdeprescribingambulatory care Behavioral Health / Addiction Medicine

Background Information

Early LAI use in schizophrenia improves outcomes and adherence.

Early intervention with long-acting injectable (LAI) antipsychotics in schizophrenia could improve outcomes significantly. LAIs used early in treatment show reduced relapse rates and lower healthcare costs. Encourages first-line use of LAIs, yet notes current underuse and need for improved clinical adoption. Consider LAIs early in schizophrenia for better adherence and outcomes.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Harrison SJ, Antunes J, Knight K, Johnston K, Mehawej J, Sanchez P, Correll CU

Citation: Harrison SJ, Antunes J, Knight K, et al. The Role of Long-Acting Injectable Antipsychotics in the Early Treatment of Schizophrenia. CNS drugs. 2026;40(7):921-948. doi:10.1007/s40263-026-01294-9

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →